The splice variants of vascular endothelial growth factor (VEGF) and their receptors.

By Christopher J. Robinson, S. Stringer. Journal of Cell Science, 2001

1,001 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/a7a7483b59270571ab9b8dd925557078c8e945a5

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Citations in the corpus

Cellular and physiological mechanisms underlying blood flow regulation in the retina choroid in health disease (2012, unknown): “Further, some isoforms of VEGF are soluble while others are bound; reviewed in Neufeld et al. (1999), Robinson and Stringer (2001).”
Interactions between extracellular matrix and growth factors in wound healing (2009, background): “Two of the three most widely expressed isoforms of VEGF, V145 and V189, bind to heparan sulfate, although the third widely expressed isoform, V121, does not.(52) Plasmin, a natural component of wound fluid, releases V145 and V189 from their bound state, thereby enabling their endothelial cell mitoge”
Vascular endothelial growth factor (VEGF) signaling in tumor progression. (2007, background): “Other rowth factors including basic fibroblast growth factor, latelet-derived growth factor [196], and several VEGF splice ariants [30] bind to extracellular matrix components.”
Function of alternative splicing. (2005, unknown): “Vascular endothelial growth factor Different receptors (Park et al., 1993; Robinson and Stringer, 2001) Wilm’s tumor protein suppressor gene Prostate apoptosis response factor par4 (Richard et al.”
Extracellular matrix and cell signalling: the dynamic cooperation of integrin, proteoglycan and growth factor receptor. (2011, background): “It has also been shown that different isoforms of VEGFs exhibit differential binding to the HS side chains of perlecan, thus affecting the VEGF signalling outcome as well as creating differential gradient of the ligand at the cell surface (Robinson & Stringer 2001, Whitelock et al .”
Ranibizumab in neovascular age-related macular degeneration (2006, unknown): “Clinical Interventions in Aging 2006:1(4) 455 peak concentrations being found at 6 hours and 1 day, respectively, and a terminal half-life of 2.6 days.”
The vascular endothelial growth factor (VEGF) family: angiogenic factors in health and disease (2005, background): “Alternative splicing of the human VEGF-A gene gives rise to at least six different transcripts (Table 2), encoding isoforms of the following lengths (in amino acids, excluding the signal peptide): 121 (120 in mouse), 145, 165 (164 in mouse), 183, 189 and 206 [20].”